Dermira (DERM) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Dermira (NASDAQ:DERM) from a hold rating to a sell rating in a research note published on Monday.

According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “

Several other brokerages have also recently weighed in on DERM. BidaskClub cut shares of Dermira from a strong-buy rating to a buy rating in a research report on Thursday, July 19th. Cantor Fitzgerald set a $20.00 price target on shares of Dermira and gave the stock a buy rating in a research report on Monday, August 6th. Finally, Needham & Company LLC set a $16.00 price target on shares of Dermira and gave the stock a buy rating in a research report on Friday, May 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $27.00.

Dermira stock opened at $9.58 on Monday. The stock has a market capitalization of $419.00 million, a price-to-earnings ratio of -2.18 and a beta of 1.47. The company has a debt-to-equity ratio of 2.49, a current ratio of 4.78 and a quick ratio of 4.78. Dermira has a 1 year low of $6.98 and a 1 year high of $31.42.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, hitting the consensus estimate of ($0.57). Dermira had a negative net margin of 761.87% and a negative return on equity of 128.21%. The firm had revenue of $39.08 million during the quarter, compared to analysts’ expectations of $39.00 million. research analysts expect that Dermira will post -5.16 earnings per share for the current fiscal year.

In related news, CEO Thomas G. Wiggans purchased 11,875 shares of the business’s stock in a transaction on Monday, June 18th. The shares were acquired at an average price of $10.10 per share, for a total transaction of $119,937.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have acquired a total of 49,805 shares of company stock worth $479,517 in the last 90 days. 14.80% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in DERM. Alpine Global Management LLC acquired a new stake in shares of Dermira in the first quarter worth $100,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Dermira in the second quarter worth $106,000. Barclays PLC increased its stake in shares of Dermira by 276.7% in the first quarter. Barclays PLC now owns 17,499 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 12,854 shares during the period. grace capital acquired a new stake in shares of Dermira in the second quarter worth $153,000. Finally, Eversept Partners LLC acquired a new stake in shares of Dermira in the first quarter worth $160,000. Hedge funds and other institutional investors own 89.21% of the company’s stock.

About Dermira

Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.

Featured Story: How Important is Technical Analysis of Stocks

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply